Chemomab Therapeutics Ltd. Q1 FY2022 earnings call

• Named Jack Lawler as Vice President of Global Clinical Development Operations, bringing over 20 years of clinical drug development experience.
• Presented data at scientific meetings: preclinical data on CM-101 for systemic sclerosis at the International Rheumatology Conference and data on CCL24 in systemic sclerosis patients at the Systemic Sclerosis World Congress.
• Progress in CM-101 clinical program: Liver fibrosis trial enrollment complete; PSC trial is recruiting and expanding sites with dose-finding cohorts; Phase 2 systemic sclerosis trial design is in progress.
• Financials: Cash, cash equivalents, and bank deposits were $57.5 million as of March 31, 2022; R&D expenses were $2.7 million for Q1 2022; G&A expenses were $2.6 million for Q1 2022; net loss was $5.1 million; cash runway expected to last through the end of 2023.

Chemomab's primary focus is the CM-101 clinical program. CM-101 is a first-in-class monoclonal antibody targeting CCL24 for indications such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). There are no traditional product segments with revenue contribution as the company is in the clinical development stage.

• Cash runway is expected to last through the end of 2023, which is six months longer than previous guidance.
• Renewed ATM facility with Cantor Fitzgerald with a current cap of about $18 million, and there are no immediate plans to draw on the facility.

Forward-looking statements are subject to risks and uncertainties as outlined in the company's SEC filings, including factors that could cause actual results to differ from forward-looking statements.

Q: Kristen Kluska asked about the role of inflammation and fibrosis in CM-101's indications and expectations for the PSC readout.

A: Adi Mor and David Weiner responded on CM-101's dual mechanism of acting on inflammation and fibrosis and that the primary purpose of the PSC interim analysis is to gather safety data for advancing to higher doses.

Q: Jeff Jones asked about PSC trial patient numbers, timing of updates, and business development activities.

A: David Weiner and Don Marvin responded on the timing of trial recruitment details, plans to provide significant updates on PSC and SSc study design in August, and that business development focus is on partnering for CM-101.

Q: Nathan Weinstein asked about the importance of the subcutaneous dosing route and OpEx trends.

A: David Weiner and Don Marvin responded on the convenience of the subcutaneous route for patient access and that OpEx will trend up as the PSC trial expands in the US and Spain and the SSc trial kicks off in the fourth quarter.